AringerM.EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum2019;
49: S14–S17.
2.
AringerMLeuchtenNJohnsonSR.New criteria for lupus. Curr Rheumatol Rep2020;
22: 18.
3.
BajemaIMWilhelmusSAlpersCE, et al.
Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int2018;
93: 789–796.
4.
HasslerJR.IgA nephropathy: a brief review. Semin Diagn Pathol2020;
37: 143–147.
5.
SoaresMFSRobertsISD.Histologic classification of IgA nephropathy: past, present, and future. Semin Nephrol2018;
38: 477–484.
6.
HagenbuchnerJRuppMSalvadorC, et al.
Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma. Oncotarget2016;
7: 77591–77606.
7.
MeliambroKCampbellKNChungM.Therapy for proliferative lupus nephritis. Rheum Dis Clin North Am2018;
44: 545–560.
8.
ZampeliEKlinmanDMGershwinMEMoutsopoulosHM.A comprehensive evaluation for the treatment of lupus nephritis. J Autoimmun2017;
78: 1–10.
9.
WilhelmusSCookHTNoelLH, et al.
Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin J Am Soc Nephrol2015;
10: 47–53.
EdelbauerMJungraithmayrTZimmerhacklLB.Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol2005;
20: 811–813.
12.
EdelbauerMKshirsagarSRiedlM, et al.
Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol2011;
26: 401–410.
13.
SolezKBernierACrichtonJ, et al.
Bridging the gap between the technological singularity and mainstream medicine: highlighting a course on technology and the future of medicine. Glob J Health Sci2013;
5: 112–125.
